SCHEMBL5690067

SCHEMBL5690067

OC(CCN[C@H]1CC[C@H](c2ccc(OCc3ccccc3)cc2)CC1)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.49
KMT2A Q03164 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
LIPG Q9Y5X9 1/20 0.48
FOXM1 Q08050 1/20 0.48
MRGPRX4 Q96LA9 1/20 0.46
MAOA P21397 4/20 0.46
MAOB P27338 4/20 0.46
KDM1A O60341 4/20 0.46
CYP2C9 P11712 1/20 0.44
HRH3 Q9Y5N1 1/20 0.44
GRIN1 Q05586 1/20 0.40
GRIN2B Q13224 1/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
PTGS1 P23219 1/20 0.40
SLC6A2 P23975 1/20 0.40
CYP2C19 P33261 1/20 0.40
PTGS2 P35354 1/20 0.40
SLC6A3 Q01959 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5690064 1.00 KDM4E (0.49) KDM4EKMT2ASMN1; SMN2LIPGFOXM1
SCHEMBL5690073 1.00 KDM4E (0.49) KDM4EKMT2ASMN1; SMN2LIPGFOXM1
SCHEMBL5690102 0.87 KDM4E (0.47) KDM4EKMT2ASMN1; SMN2LIPGFOXM1
SCHEMBL5689745 0.87 KDM4E (0.47) KDM4EKMT2ASMN1; SMN2LIPGFOXM1
SCHEMBL5689751 0.87 KDM4E (0.47) KDM4EKMT2ASMN1; SMN2LIPGFOXM1
SCHEMBL5689738 0.87 KDM4E (0.47) KDM4EKMT2ASMN1; SMN2LIPGFOXM1
SCHEMBL5691903 0.86 MRGPRX4 (0.46) KMT2ASMN1; SMN2LIPGMRGPRX4MAOA
SCHEMBL5689684 0.85 GRIN2B (0.45) KDM4ESMN1; SMN2CYP2C9GRIN1GRIN2B
SCHEMBL5689681 0.85 GRIN2B (0.45) KDM4ESMN1; SMN2CYP2C9GRIN1GRIN2B
SCHEMBL5690088 0.82 FOXM1 (0.55) KDM4EKMT2ASMN1; SMN2LIPGFOXM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0982026-B1 Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers HOFFMANN LA ROCHE (CH) 2006-05-17 EP disclosed
US-6184236-B1 Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative HOFFMANN-LA ROCHE INC. 2001-02-06 US disclosed
EP-0982026-A2 Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers F. HOFFMANN-LA ROCHE AG (CH) 2000-03-01 EP disclosed